title: Bilateral sequential nonarteritic anterior ischemic optic neuropathy: a comparison of visual outcomes in fellow eyes using quantitative analysis of goldmann visual fields.
abstract: OBJECTIVE
  To better define the concordance of visual loss in patients with nonarteritic anterior ischemic optic neuropathy (NAION).
  
  
  METHODS
  The medical records of 86 patients with bilateral sequential NAION were reviewed retrospectively, and visual function was assessed using visual acuity, Goldmann visual fields, color vision, and relative afferent papillary defect. A quantitative total visual field score and score per quadrant were analyzed for each eye using the numerical Goldmann visual field scoring method.
  
  
  RESULTS
  Outcome measures were visual acuity, visual field, color vision, and relative afferent papillary defect. A statistically significant correlation was found between fellow eyes for multiple parameters, including logMAR visual acuity (P=.01), global visual field (P<.001), superior visual field (P<.001), and inferior visual field (P<.001). The mean deviation of total (P<.001) and pattern (P<.001) deviation analyses was significantly less between fellow eyes than between first and second eyes of different patients.
  
  
  CONCLUSIONS
  Visual function between fellow eyes showed a fair to moderate correlation that was statistically significant. The pattern of vision loss was also more similar in fellow eyes than between eyes of different patients. These results may help allow better prediction of visual outcome for the second eye in patients with NAION.
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 46290, USA.
authors: Jennifer Loh
authors: JL
authors: Mercado
authors: Valerie A
authors: VA
authors: Purvin
authors: Aki
authors: A
authors: Kawasaki
authors: Darrell
authors: D
authors: WuDunn
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage; D055253:Color Vision / Q000502:physiology; D005260:Female; D013700:Giant Cell Arteritis / Q000503:physiopathology; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy / Q000503:physiopathology*; D011448:Prostaglandin Antagonists / Q000008:administration & dosage; D011681:Pupil Disorders / Q000503:physiopathology; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology*; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D005938:Glucocorticoids; D011448:Prostaglandin Antagonists; D001241:Aspirin